AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05660811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: long-term treatment with a single antiplatelet agent
Description: continuing long-term treatment with single antiplatelet agent
Study NCT05660811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 6 months treatment with a single antiplatelet agent
Description: continuing single antiplatelet agent up until 6 months
Study NCT06239207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)
Description: Exosomes used are GFC CELL, consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP Pep9 solution
Study NCT06239207 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP is prepared under aseptic precautions, around 10ml of blood is collected in PRP tubes which are rotated in a centrifuge machine at 1500 RPM for 10 minutes. Which separates the blood into 2 layers: the lower RBC layer; the upper acellular plasma layer. The buffy coat along with the plasma was collected with a pipette and transferred into another test tube underwent 2nd spin at 4000 RPM for 10 min. This PRP was collected in another clean tube to be used as plasma
Study NCT04668157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granule formulation
Study NCT06199479 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Scan
Description: Performed by MRI Scan
Study NCT06199479 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT Scan
Description: Performed by CT Scan
Study NCT06199479 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Standard of Care Biopsy
Study NCT06445959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO
Study NCT06445959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT06445959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV
Study NCT06420206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Acute Cancer Care Center)
Description: In Group 1, participants will receive the usual standard of care by an emergency care physician not trained in palliative care.
Study NCT06420206 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (Goals of Care)
Description: In Group 2, participants will receive standard of care plus palliative care intervention by an emergency care physician trained in palliative care.
Study NCT05660070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile Social Interaction Therapy by Exposure (mSITE)
Description: mSITE is a blended intervention that integrates brief in-person psychotherapy with context-triggered mobile smartphone intervention and remote telephone coaching.
Study NCT06300047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Medical Transition Coordinator
Description: Participants in this intervention arm will have access to the non-medical transition coordinator to support their transition from pediatric to adult care.
Study NCT06137040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate within the first hour
Description: The experimental group will receive 40-50 mg/kg of IV magnesium sulfate will be given to the experimental group alongside the first line asthma therapies (ie inhaled beta agonists, IV steroids). This will be given with a 20 mL/kg normal saline bolus (max 1000 mL) to avoid possible hypotension.~15-19 kg: 750 mg~20-29 kg: 1000 mg~30-39 kg: 1500 mg~>40 kg: 2000 mg
Study NCT06137040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Magnesium sulfate within the first hour
Description: The control group will not receive IV magnesium sulfate within the first hour of treatment.
Study NCT05705310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management Strategies
Description: During their maintenance stage cardiac rehabilitation programme, participants will be given a pedometer and asked to wear it during waking hours to record their daily step counts and/or time in physical activity each week. Participants will be encouraged to gradually achieve 150 minutes of moderate-intensity exercise per week and self-monitor their progress using the pedometer. At the end of every week, participants will review progress and set goals with an exercise professional. Group discussions will also take place, focusing on the benefits of regular physical activity, demonstrating lifestyle activities that can help accumulate activity and identifying various means of social support, and identifying local opportunities (groups or places) for physical activity after the cardiac rehabilitation programme has ended. Following this, they will receive a monthly phone call from the exercise professional to check progress and encourage them to continue with the programme.
Study NCT05372614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative studies
Study NCT05372614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05372614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05372614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT05372614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT05372614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Maleate
Description: Given PO
Study NCT05372614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT05017116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: subcutaneous injection
Study NCT05017116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection
Study NCT05017116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Take orally.
Study NCT04463719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling using the electronic conversation aid
Description: Patients receive counseling about thyroid biopsy with the use of the conversation aid.
Study NCT05465343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 160mg orally QD
Study NCT04463719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling by routine care
Description: Patients receive counseling by routine care without the use of the conversation aid
Study NCT05846659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Study NCT05846659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
Study NCT05846659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: 1st infusion on Cycle 1 Day 2, and then thereafter as per product label.
Study NCT05846659 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study NCT05846659 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PULSAR
Description: 1st day of Cycles 1, 2 and 3.
Study NCT05636943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Intimacy Enhancement
Description: Participants attend four virtual sessions (60-75 minutes) with a couples' coach consisting of education and skills training to enhance physical and emotional intimacy.
Study NCT05636943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Facts and Resources
Description: Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
Study NCT05636943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intimacy Facts and Resources
Description: Self-guided booklet of readings/resources about intimacy and metastatic breast cancer
Study NCT05734534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR during training
Description: Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
Study NCT05734534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR during training
Description: Healthy participants and participants diagnosed with COPD will be randomized to either the BFR-ST and BFR-HIT or to HL-ST and HIT
Study NCT05734534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BFR during rest
Description: Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
Study NCT04852198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OAGB
Description: Simplified gastric bypass procedure
Study NCT05734534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BFR during rest
Description: Participants experiencing acute exacerbation of their COPD requiring hospitalization will be randomized to either BFR-P, BFR-NMES or the control group throughout their hospitalization.
Study NCT04852198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: Roux-en-Y gastric bypass. Standard procedure in the Netherlands
Study NCT06236685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric impedance tomography
Description: EIT is rarely used during general anesthesia for standard procedures. In the anesthesia arm, all patients will be monitored by EIT.
Study NCT04678180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined HRT and ERP
Description: tic training using the principles of HRT and ERP as to reduce tic intensity
Study NCT04607356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Description: The Delphi Personalized Tourniquet System (PTS) will be utilized for the BFR exercises. The external constriction device will be applied to the proximal aspect of an individual's limb to restrict the flow of blood into and out of the extremity at 50% of usual flow. Subjects will perform a 30-15-15-15 repetition progression of 1-3 exercises as selected by the therapist. The Delphi PTS cuff is inflated at the start of the exercise and remains inflated throughout the exercise. Once the participant has completed an exercise, the cuff is deflated for 1 minute and the same cycle is performed for each subsequent exercise.
Study NCT06234566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dental implant surgery
Description: It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed with serum irrigation at a speed of 800 rpm.
Study NCT06234566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Speed Drilling Without Irrigation
Description: It is performed to reconstruct lost teeth. These are surgical procedures performed to place dental implants in the jaw bones. To prepare the implant socket, drilling is performed at a speed of 50 rpm without serum irrigation.
Study NCT04607356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-informed care
Description: Evidence-based resistive exercises, stretches, soft tissue mobilization and patient education for lateral epicondylalgia.
Study NCT05324774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW0813
Description: The active ingredient of 9MW0813 injection is recombinant human vascular endothelial growth factor receptor-antibody fusion protein.~9 doses(2mg) of the drug will be injected intravitreously.
Study NCT05324774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept (trade name: Eylea®/EYLEA®) is an anti-VEGF drug developed by Regeneron/Bayer. It is a fusion protein of human VEGFR1 and VEGFR2 extracellular domains and human immunoglobulin Fc segment genes.~9 doses(2mg) of the drug will be injected intravitreously.
Study NCT06090227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Standard of Care
Description: Administration of daily oral extended-release Metformin 500 mg tablets with standard of care for 6 months.
Study NCT06090227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Standard of Care
Description: Administration of daily placebo tablets with standard of care for 6 months.
Study NCT05248633 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy with a dose of 40-50 Gy
Study NCT05248633 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy with a dose of 40-50 Gy
Study NCT05248633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: subcutaneous Bortezomib 1.3mg/m2 d1,8,15,22
Study NCT05248633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg for 21 days
Study NCT05248633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg d1,8,15,22
Study NCT05740943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Patients were assigned to receive oral lorlatinib at a dose of 100 mg daily in a course of treatment that was measured in cycles of 28 days. 3 cycles of induction treatment will be required for the study.
Study NCT05973422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGI Insulin Management System
Description: Continuous subcutaneous insulin infusion with Sigi, and wearing the Dexcom G7 sensor using the Dexcom App.
Study NCT04795674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM Training
Description: Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
Study NCT04795674 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: Computerized tasks with comparable engagement that do not tap executive working memory processes
Study NCT03952416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation (EMR)
Description: EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity).
Study NCT06262113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters about NF1 Care (Content Type 1)
Description: Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
Study NCT06262113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letters about NF1 Care (Content Type 2)
Description: Participants will receive two letters about NF1 care, one for themselves and one for their primary care clinician, to read in advance of the patient's annual wellness visit
Study NCT05637827 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in each group, and only the natural development was observed
Study NCT05373264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Description: An oral capsule containing 25mg of hydrochlorothiazide
Study NCT05373264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching oral capsule containing placebo
Study NCT06122974 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Drug Eluting Temporary Spur Stent System
Description: The Spur Stent consists of a sirolimus coated stent and balloon that is retrievable after delivery of the sirolimus formulation.
Study NCT06122974 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Transluminal Balloon Angioplasty
Description: A balloon catheter is inserted across a lesion and inflated to fracture and compress the plaque, creating a larger lumen and improved blood flow through the artery.
Study NCT04854096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-018
Description: Experimental
Study NCT04854096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Active Comparator
Study NCT04633928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-TEC: Autologous nasal chondrocytes and ECM proteins
Description: Cells expanded in vitro and cultured in a collagen type I//III scaffold
Study NCT06255652 — intervention group
Intervention type: DRUG
Intervention: Cephradin
Description: Velosef
Study NCT06249282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06249282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06249282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT06239727 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F.
Study NCT06239727 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.
Study NCT06249282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06249282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06249282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06249282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study NCT06239727 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional-dose Intensity-modulated radiotherapy
Description: 1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day~2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.
Study NCT04800146 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Patients will be asked to provide blood samples at specified time points: before and after the SARS-CoV-2 vaccination
Study NCT06273228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study NCT05670470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0303
Description: Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
Study NCT05670470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orafang Tab
Description: Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study NCT06239727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
Study NCT05387889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation for Pulmonary Hypertension (MMPH)
Description: Eight weeks of Mindfulness Meditation practice for patients with Pulmonary Hypertension condition. The content will focus on how to apply Mindfulness concepts to the everyday management of symptoms and stress.